A novel subtype to predict prognosis and treatment response with DNA driver methylation–transcription in ovarian cancer

References

• Jayson GC , KohnEC , KitchenerHCet al. Ovarian cancer. The Lancet384(9951), 1376–1388 (2014).
   PubMed Web of Science ®Google Scholar
• Nash Z , MenonU. Ovarian cancer screening: current status and future directions. Best. Pract. Res. Clin. Obstet. Gynaecol.65, 32–45 (2020).
   PubMed Web of Science ®Google Scholar
• Jimenez-Sanchez A , MemonD , PourpeSet al. Heterogeneous tumor-immune microenvironments among differentially growing metastases in an ovarian cancer patient. Cell170(5), 927–938 e20 (2017).
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research N . Integrated genomic analyses of ovarian carcinoma. Nature474(7353), 609–15 (2011).
   PubMed Web of Science ®Google Scholar
• Matz M , ColemanMP , SantMet al. The histology of ovarian cancer: worldwide distribution and implications for international survival comparisons (CONCORD-2). Gynecol. Oncol.144(2), 405–413 (2017).
   PubMed Web of Science ®Google Scholar
• Bowtell DD , BohmS , AhmedAAet al. Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nat. Rev. Cancer15(11), 668–79 (2015).
   PubMed Web of Science ®Google Scholar
• Kuroki L , GuntupalliSR. Treatment of epithelial ovarian cancer. BMJ371, m3773 (2020).
   PubMedGoogle Scholar
• Franzese E , CentonzeS , DianaAet al. PARP inhibitors in ovarian cancer. Cancer. Treat. Rev.73, 1–9 (2019).
   PubMed Web of Science ®Google Scholar
• Mirza MR , PignataS , LedermannJA. Latest clinical evidence and further development of PARP inhibitors in ovarian cancer. Ann. Oncol.29(6), 1366–1376 (2018).
   PubMed Web of Science ®Google Scholar
• Pujade-Lauraine E . New treatments in ovarian cancer. Ann. Oncol.28(Suppl. 8), viii57–viii60 (2017).
   PubMed Web of Science ®Google Scholar
• Hamanishi J , MandaiM , IkedaTet al. Safety and antitumor activity of Anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer. J. Clin. Oncol.33(34), 4015–22 (2015).
   PubMed Web of Science ®Google Scholar
• Varga A , Piha-PaulSA , OttPAet al. Antitumor activity and safety of pembrolizumab in patients (pts) with PD-L1 positive advanced ovarian cancer: interim results from a phase Ib study. J. Clin. Oncol.33(Suppl. 15), 5510–5510 (2015).
   Google Scholar
• Gevaert O , TibshiraniR , PlevritisSK. Pancancer analysis of DNA methylation-driven genes using MethylMix. Genome. Biol.16, 17 (2015).
   PubMed Web of Science ®Google Scholar
• Feng LY , YanBB , HuangYZet al. Abnormal methylation characteristics predict chemoresistance and poor prognosis in advanced high-grade serous ovarian cancer. Clin. Epigenetics13(1), 141 (2021).
   PubMed Web of Science ®Google Scholar
• Bodelon C , KillianJK , SampsonJNet al. Molecular classification of epithelial ovarian cancer based on methylation profiling: evidence for survival heterogeneity. Clin. Cancer. Res.25(19), 5937–5946 (2019).
   PubMed Web of Science ®Google Scholar
• Yang Y , WuL , ShuXet al. Genetic data from nearly 63,000 women of European descent predicts DNA methylation biomarkers and epithelial ovarian cancer risk. Cancer. Res.79(3), 505–517 (2019).
   PubMed Web of Science ®Google Scholar
• Villanueva L , Alvarez-ErricoD , EstellerM. The Contribution of epigenetics to cancer immunotherapy. Trends. Immunol.41(8), 676–691 (2020).
   PubMed Web of Science ®Google Scholar
• Pfeifer GP . Defining driver DNA methylation changes in human cancer. Int. J. Mol. Sci.19(4), 1166 (2018).
   PubMed Web of Science ®Google Scholar
• Kalari S , PfeiferGP. Identification of driver and passenger DNA methylation in cancer by epigenomic analysis. Adv. Genet.70, 277–308 (2010).
   PubMed Web of Science ®Google Scholar
• Spainhour JC , LimHS , YiSVet al. Correlation patterns between DNA methylation and gene expression in The Cancer Genome Atlas. Cancer. Inform.18, 1176935119828776 (2019).
   Web of Science ®Google Scholar
• Zhang B , KusterB. Proteomics is not an island: multi-omics integration is the key to understanding biological systems. Mol. Cell. Proteomics18(8 Suppl. 1), S1–S4 (2019).
   PubMed Web of Science ®Google Scholar
• Patch AM , ChristieEL , EtemadmoghadamDet al. Whole-genome characterization of chemoresistant ovarian cancer. Nature.521(7553), 489–94 (2015).
   PubMed Web of Science ®Google Scholar
• Zhang W , KlinkebielD , BargerCJet al. Global DNA hypomethylation in epithelial ovarian cancer: passive demethylation and association with genomic instability. Cancers12(3), 764 (2020).
   PubMed Web of Science ®Google Scholar
• Bailey MH , TokheimC , Porta-PardoEet al. Comprehensive characterization of cancer driver genes and mutations. Cell173(2), 371–385 e18 (2018).
   PubMed Web of Science ®Google Scholar
• Ahmed AA , EtemadmoghadamD , TempleJet al. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J. Pathol.221(1), 49–56 (2010).
   PubMed Web of Science ®Google Scholar
• Pan H , RenaudL , ChaligneRet al. Discovery of candidate DNA methylation cancer driver genes. Cancer Discov.11(9), 2266–2281 (2021).
   PubMed Web of Science ®Google Scholar
• Chen CL , RappaillesA , DuquenneLet al. Impact of replication timing on non-CpG and CpG substitution rates in mammalian genomes. Genome Res.20(4), 447–57 (2010).
   PubMed Web of Science ®Google Scholar
• Wang B , MezliniAM , DemirFet al. Similarity network fusion for aggregating data types on a genomic scale. Nat. Methods11(3), 333–7 (2014).
   PubMed Web of Science ®Google Scholar
• Ashburner M , BallCA , BlakeJAet al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat. Genet.25(1), 25–9 (2000).
   PubMed Web of Science ®Google Scholar
• Kanehisa M , GotoS. KEGG: kyoto encyclopedia of genes and genomes. Nucleic. Acids. Res.28(1), 27–30 (2000).
   PubMed Web of Science ®Google Scholar
• Subramanian A , TamayoP , MoothaVKet al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA102(43), 15545–15550 (2005).
   PubMed Web of Science ®Google Scholar
• Chang X , DongY. CACNA1C is a prognostic predictor for patients with ovarian cancer. J. Ovarian. Res.14(1), 88 (2021).
   PubMed Web of Science ®Google Scholar
• Chang P , ChenS , ChangXet al. EXTL3 could serve as a potential biomarker of prognosis and immunotherapy for prostate cancer and its potential mechanisms. Eur. J. Med. Res.27(1), 115 (2022).
   PubMed Web of Science ®Google Scholar
• Drakes ML , StiffPJ. Regulation of ovarian cancer prognosis by immune cells in the tumor microenvironment. Cancers10(9), 302 (2018).
   PubMed Web of Science ®Google Scholar
• Bagaev A , KotlovN , NomieKet al. Conserved pan-cancer microenvironment subtypes predict response to immunotherapy. Cancer Cell.39(6), 845–865 e7 (2021).
   PubMed Web of Science ®Google Scholar
• Mak MP , TongP , DiaoLet al. A patient-derived, pan-cancer EMT signature identifies global molecular alterations and immune target enrichment following epithelial-to-mesenchymal transition. Clin. Cancer Res.22(3), 609–20 (2016).
   PubMed Web of Science ®Google Scholar
• Chen H , YaoJ , BaoRet al. Cross-talk of four types of RNA modification writers defines tumor microenvironment and pharmacogenomic landscape in colorectal cancer. Mol. Cancer20(1), 29 (2021).
   PubMed Web of Science ®Google Scholar
• Thorsson V , GibbsDL , BrownSDet al. The immune landscape of cancer. Immunity48(4), 812–830 e14 (2018).
   PubMed Web of Science ®Google Scholar
• Yoshihara K , ShahmoradgoliM , MartinezEet al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat. Commun.4, 2612 (2013).
   PubMed Web of Science ®Google Scholar
• Jiang P , GuS , PanDet al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat. Med.24(10), 1550–1558 (2018).
   PubMed Web of Science ®Google Scholar
• Charoentong P , FinotelloF , AngelovaMet al. Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade. Cell. Rep.18(1), 248–262 (2017).
   PubMed Web of Science ®Google Scholar
• Hoshida Y , BrunetJP , TamayoPet al. Subclass mapping: identifying common subtypes in independent disease data sets. PLOS ONE2(11), e1195 (2007).
   PubMed Web of Science ®Google Scholar
• Roh W , ChenP-L , ReubenAet al. Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Sci. Transl. Med.9(379), eaah3560 (2017).
   PubMed Web of Science ®Google Scholar
• Rosenberg JE , Hoffman-CensitsJ , PowlesTet al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. The Lancet387(10031), 1909–1920 (2016).
   PubMed Web of Science ®Google Scholar
• Sun XX , YuQ. Intra-tumor heterogeneity of cancer cells and its implications for cancer treatment. Acta. Pharmacol. Sin.36(10), 1219–27 (2015).
   PubMed Web of Science ®Google Scholar
• Liu R , HuR , ZengYet al. Tumour immune cell infiltration and survival after platinum-based chemotherapy in high-grade serous ovarian cancer subtypes: A gene expression-based computational study. EBioMedicine51, 102602 (2020).
   PubMed Web of Science ®Google Scholar
• Papp E , HallbergD , KonecnyGEet al. Integrated genomic, epigenomic, and expression analyses of ovarian cancer cell lines. Cell. Rep.25(9), 2617–2633 (2018).
   PubMed Web of Science ®Google Scholar
• Reid BM , FridleyBL. DNA Methylation in ovarian cancer susceptibility. Cancers13(1), 108 (2020).
   PubMed Web of Science ®Google Scholar
• Matthews BG , BowdenNA , Wong-BrownMW. Epigenetic mechanisms and therapeutic targets in chemoresistant high-grade serous ovarian cancer. Cancers13(23), 5993 (2021).
   PubMed Web of Science ®Google Scholar
• Shen H , FridleyBL , SongHet al. Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. Nat. Commun.4, 1628 (2013).
   PubMed Web of Science ®Google Scholar
• Bubancova I , KovarikovaH , LacoJet al. Next-generation sequencing approach in methylation analysis of HNF1B and GATA4 genes: searching for biomarkers in ovarian cancer. Int. J. Mol. Sci.18(2), 474 (2017).
   PubMed Web of Science ®Google Scholar
• Maeda O , AndoT , OhmiyaNet al. Alteration of gene expression and DNA methylation in drug-resistant gastric cancer. Oncol. Rep.31(4), 1883–90 (2014).
   PubMed Web of Science ®Google Scholar
• Reilly PT , MakTW. Molecular pathways: tumor cells co-opt the brain-specific metabolism gene CPT1C to promote survival. Clin. Cancer. Res.18(21), 5850–5 (2012).
   PubMed Web of Science ®Google Scholar
• Han J , DuanJ , BaiHet al. TCR repertoire diversity of peripheral PD-1(+)CD8(+) T cells predicts clinical outcomes after immunotherapy in patients with non-small cell lung cancer. Cancer Immunol. Res.8(1), 146–154 (2020).
   PubMed Web of Science ®Google Scholar
• Kim SS , SumnerWA , MiyauchiSet al. Role of B cells in responses to checkpoint blockade immunotherapy and overall survival of cancer patients. Clin. Cancer. Res.27(22), 6075–6082 (2021).
   PubMed Web of Science ®Google Scholar
• Datta M , CoussensLM , NishikawaHet al. Reprogramming the tumor microenvironment to improve immunotherapy: emerging strategies and combination therapies. Am. Soc. Clin. Oncol. Educational Book.39, 165–174 (2019).
   PubMedGoogle Scholar
• Tang H , QiaoJ , FuYX. Immunotherapy and tumor microenvironment. Cancer Lett.370(1), 85–90 (2016).
   PubMed Web of Science ®Google Scholar
• Goodman AM , KatoS , BazhenovaLet al. Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. Mol. Cancer. Ther.16(11), 2598–2608 (2017).
   PubMed Web of Science ®Google Scholar
• Morand S , DevanaboyinaM , StaatsHet al. Ovarian cancer immunotherapy and personalized medicine. Int. J. Mol. Sci.22(12), 6532 (2021).
   PubMed Web of Science ®Google Scholar
• Maleki Vareki S . High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors. J. Immunother. Cancer6(1), 157 (2018).
   PubMedGoogle Scholar
• Perez-Guijarro E , YangHH , ArayaREet al. Multimodel preclinical platform predicts clinical response of melanoma to immunotherapy. Nat. Med.26(5), 781–791 (2020).
   PubMed Web of Science ®Google Scholar
• Shapiro E , BiezunerT , LinnarssonS. Single-cell sequencing-based technologies will revolutionize whole-organism science. Nat. Rev. Genet.14(9), 618–630 (2013).
   PubMed Web of Science ®Google Scholar